Skip to content

“HHS should consider using march-in rights when drugs face limited competition or market practices have failed to ensure an affordable price, ensuring that prescription drugs invented with taxpayer dollars are reasonably priced and affordable.”

Is it true?

Misleadingaccording to Washington Post

Washington Post checked this claim.

“Lacks context”

  1. English

    Read the fact-check at Washington Post

Related

Something wrong here? Report it by emailinfo@factiz.org

The verdict belongs to the newsroom: report an error in it to them, through their article above. Report an error in what Factiz added, such as the translation, the theme or the names, to us.

Record from: Data Commons (ClaimReview feed), with the fact-check of the newsroom named. Licence: CC BY 4.0. Factiz added the language, the verdict category and the grouping of the same claim.

The sources are the verdict.